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I.  INTRODUCTION 
“It made my heart thump, for I was certain it was gold.”1  James Marshall 
uttered these words when he discovered gold flakes at the Sutter’s Mill in 
Coloma, California.2  As word spread, thousands of miners rushed to California 
in search of riches, in what was known as the Gold Rush of 1849.3  Now, 
America has a new rush—the “green” rush,4 and once again, it is centered in 
the American West. 
Marijuana, formally known as cannabis,5 is on the brink of becoming a 
legitimate business.  Despite a long history of medical use and recreational 
consumption dating back to ancient times, marijuana regulation is a recent 
development.6  Popularly known as “weed,” many believe cannabis culture is a 
counterculture aimed at destroying societal wellbeing in many ways.7 
Recent state legalization allowing the recreational use and commercialization 
of cannabis in four jurisdictions8 has caught the eye of eager entrepreneurs, 
especially innovators of the product.  However, legal impediments at the federal 
level9 hinder innovation in the cannabis industry from properly budding.  As a 
result, scarce legal precedent exists for cannabis in the patent law arena.  Given 
the federal prohibition on marijuana, patenting strains of the cannabis plant, 
and its derivative products, would seem to likely be prohibited.  The word 
“likely” is used because, despite criminal legal impediments, marijuana has been 
patented,10 and more cannabis products are patent-pending.11 
                                                                                                                   
 1 The Discovery of Gold, http://memory.loc.gov/ammem/cbhtml/cbgold.html (last visited Jan. 
4, 2015). 
 2 Id. 
 3 Id. 
 4 Medical Marijuana: Will Colorado’s “Green Rush” Last?, http://www.cbsnews.com/videos/medi 
cal-marijuana-will-colorados-green-rush-last-3/ (last visited Nov. 15, 2015). 
 5 Cannabis is used throughout this Note because it is the scientific name for marijuana.  The 
terms “cannabis” and “marijuana” will be used interchangeably. 
 6 Dope Etc., FRONTLINE ON PBS, http://www.pbs.org/wgbh/pages/frontline/shows/dope/ 
etc/cron.html (last visited Oct. 20, 2015).  The Pure Food and Drug Act was the first law in 
United States history that required cannabis to be labeled in food and drug products.  The Pure 
Food and Drug Act, 34 Stat. 768 (1906). 
 7 Marijuana: Public Enemy Number One?, Urban Greenhouse (July 6, 2015), http://urbangreenh 
ouse.com/marijuana-public-enemy-number-one/. 
 8 See COLO. CONST. art. XVIII, § 16 (2013); WASH. ADMIN. CODE §§ 314-55-005 to 314-55-
540 (2013).  Recently, Oregon, Alaska, and the District of Columbia have legalized recreational 
marijuana. 
 9 The Controlled Substances Act, 21 U.S.C. § 801 (1970). 
 10 Cannabinoids as Antioxidants and Neuroprotectants, U.S. Patent No. 6630507 (filed Feb. 2, 
2001) (issued Oct. 7, 2003). 
 11 See infra Part II. 
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While a cannabis method-of-use patent has been granted to the federal 
government,12 a unique cannabis strain has never been patented.  This Note 
seeks to find concrete answers for a grower interested in patenting his or her 
unique cannabis strain.  Because this is a novel patentable subject matter, this 
Note will explore patents in other industries that faced the same legal challenges 
afflicting cannabis variety patents.  This Note asserts that equal challenges in 
other industries burden innovation in the cannabis industry. 
This Note concentrates on the legal gray area around cannabis variety 
patents and how this uncertainty affects innovation.  Part II outlines the legal 
environment surrounding marijuana patents and begins with a brief history of 
cannabis.  Part II will explore the cannabis plant and discuss the federal ban on 
marijuana, state legalization for both medicinal and recreational use, and federal 
enforcement discretion on cannabis.  Part II will survey utility and plant patents 
and potentially applicable case law analogous to the novel patentable subject 
matter discussed here.  Lastly, Part II will conclude by discussing current 
patents granted for cannabis and patent-pending developments. 
Part III will seek to demystify the legal fog surrounding cannabis variety 
patents by identifying the underlying issues and presenting clear answers.  Part 
III will then conceptualize an analytical framework for cannabis cultivators 
navigating this new patentable subject matter.  Next, Part III will assert that, 
despite federal opposition, cannabis variety patents are legal, given case law 
from the Supreme Court and Federal Circuit, as well as the policy 
considerations underlying patent law.  Finally, Part III will identify legislative 
developments that would change the legal environment.  Part IV will conclude 
that although cannabis cultivation is federally prohibited, policy considerations 
underlying plant patents and the case law from the Federal Circuit indicate 
cannabis varieties are likely patentable. 
II.  BACKGROUND 
To outline the legal environment surrounding patent law, this Part will look 
to the history of cannabis, popular culture, and law that has shaped the current 
state of the cannabis industry.  Then, this Part will explain the cannabis plant 
itself, its physical characteristics, and the patentable end products from the 
growth process.  This Part will go on to discuss the federal ban on marijuana, 
recent state legislation, and the federal governments prosecutorial discretion.  
Next, this Part will survey the statutory and policy background of utility and 
                                                                                                                   
 12 Cannabinoids as Antioxidants and Neuroprotectants, U.S. Patent No. 663507 (filed Feb. 2, 
2001) (issued Oct. 7, 2003). 
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plant patents, and potentially applicable case law from the Supreme Court and 
the Federal Circuit.  Lastly, this Part will examine previous patents for cannabis 
and patent-pending developments. 
A.  A BRIEF HISTORY OF CANNABIS LAW AND CULTURE 
Cannabis has a history dating back to ancient times.  The cannabis plant 
likely originated from Southeast Asia.13  The father of Chinese medicine, Shen 
Nung, utilized cannabis for medicinal purposes.14  From Asia, the cannabis 
plant spread to other parts of the world, including Europe.15  Hemp is a fibrous 
by-product of cannabis that has many applications.16  Hemp fibers were used to 
make sails for ships, fabric, and other products in colonial America.17 In fact, 
George Washington and Thomas Jefferson grew hemp on their plantations.18 
Cannabis and most drugs enjoyed no regulation until the twentieth 
century.19  After the Shanghai Opium Commission and Hague International 
Opium Convention, Congress passed the Harrison Narcotics Tax Act of 
1914.20  The Act did not explicitly prohibit marijuana, but placed a tax on 
opiates to induce a suppression of drug markets.21 
In subsequent years, popular culture shaped legislative efforts concerning 
marijuana.  In 1936, the film Reefer Madness sought to persuade the American 
public of the dangers of marijuana use.22  The film portrayed teenagers who 
became addicted to marijuana and committed acts of violence.23  One year later, 
Congress passed the Marihuana Tax Act of 1937.24  The Act did not criminalize 
                                                                                                                   
 13 The Origins of Cannabis, http://www.deamuseum.org/ccp/cannabis/history.html (last visited 
Nov. 15, 2015). 
 14 Yearbook of the United States Department of Agriculture 1913, Internet Archive, 288, https:// 
archive.org/stream/yoa1913#page/n327/mode/2up (last visited Nov. 15, 2015). 
 15 Map of Cannabis Spread, http://www.nhm.ac.uk/resources/nature-online/life/plants-fungi/ 
seeds-of-trade/images/maps/hemp.gif (last visited Nov. 15, 2015). 
 16 Oscar H. Will, The Forgotten History of Hemp Cultivation in America, http://www.farmcollector. 
com/farm-life/strategic-fibers.aspx#axzz3FzIQGeeM (last visited Nov. 15, 2015). 
 17 Id. 
 18 Gene Johnson, A History of Pot, from George Washington to Legalizing Ganja, NBC NEWS (Dec. 6, 
2012, 6:03 AM), http://usnews.nbcnews.com/_news/2012/12/06/15726635-a-history-of-pot-fr 
om-george-washington-to-legalizing-ganja. 
 19 German Lopez, Timeline: 100 Years of Drug Prohibition, VOX (Sept. 9, 2014, 6:00 AM), http:// 
www.vox.com/2014/9/9/6104179/the-history-of-the-war-on-drugs. 
 20 Id. 
 21 Harrison Narcotics Act of 1914, 38 Stat. 785 (repealed 1970). 
 22 Reefer Madness, http://www.imdb.com/title/tt0028346/ (last visited Nov. 15, 2015). 
 23 Id. 
 24 Marihuana Tax Act of 1937, 50 Stat. 551 (1937), repealed by Leary v. United States, 395 U.S. 6 
(1969). 
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marijuana, but required people who dealt cannabis and its by-products to 
register with the federal government and pay a prohibitive occupational tax.25  
In 1969, the Supreme Court, under Chief Justice Earl Warren, struck down the 
Marihuana Tax Act.  The Court found that the Act violated constitutional 
protections of self-incrimination by requiring persons dealing with marijuana to 
admit to trafficking by reporting to the Internal Revenue Service.26  This 
concern, enunciated by the Warren Court, resonates for cultivators applying for 
cannabis variety patents today.27 
Marijuana, along with other drugs like LSD, was integral to the 
counterculture movement in the 1960’s.28  Along with the Vietnam War, 
cannabis usage was at the forefront of the American political conscious.29  Most 
notably, Ken Kesey and the Pranksters set out across the country in a “magic” 
bus openly promoting the use of psychedelic drugs.30   
Cannabis was officially prohibited in the Controlled Substances Act (CSA) 
in 1970 during the presidency of Richard Nixon.31  The CSA was the first 
congressional act that actually criminalized marijuana.32  The congressional 
findings under the CSA state, “[t]he illegal importation, manufacture, 
distribution, and possession and improper use of controlled substances have a 
substantial and detrimental effect on the health and general welfare of the 
American people.”33  Further, Congress enacted the CSA out of concern for the 
production and distribution of controlled substances into interstate channels.34  
Under the Act, drugs are classified into schedules.35  Schedule I drugs are 
substances that have a high potential for abuse, no currently accepted medical 
treatment in the United States, and which are not safe for use under medical 
supervision.36  Cannabis is classified as a Schedule I drug.37 
                                                                                                                   
 25 Id. 
 26 Leary v. United States, 395 U.S. 6 (1969). 
 27 See infra Part III. 
 28 The 1960’s Hippie Counter Movement, Mortal Journey, http://www.mortaljourney.com/2011/ 
03/1960-trends/hippie-counter-culture-movement (last visited Oct. 20, 2015). 
 29 A Brief History of How War Gets Us Hooked on Drugs, Motherboard (Jan. 8, 2013, 4:00 PM), 
http://motherboard.vice.com/blog/how-war-getsyou-hooked. 
 30 MAGIC TRIP (Magnolia Pictures 2011).  
 31 Controlled Substances Act, 21 U.S.C.S. § 801 (1970). 
 32 See Lopez, supra note 19. 
 33 21 U.S.C. § 801(2) (2012). 
 34 Id. 
 35 Id. § 812(a). 
 36 Id. § 812(b)(1). 
 37 Drug Enforcement Agency, Drug Scheduling, http://www.justice.gov/dea/druginfo/ds.shtml 
(last visited Nov. 15, 2015). 
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After the passage of the CSA, President Nixon encouraged Congress to 
enact legislation to enforce the CSA.38  He declared that drugs were “public 
enemy number one.”39  This federal prohibition on cannabis and other 
substances would popularly be known as the “War on Drugs.”40  Later, 
Presidents Ronald Reagan and George H.W. Bush increased penalties for drug 
laws.41 
Recently, however, public support for cannabis has changed.  For example, a 
1969 Gallup poll found public support for marijuana among twelve percent of 
the American populous.42  But, in 2013, the same Gallup poll found fifty-eight 
percent of Americans support legalization of marijuana.43  Additionally, sixty-
nine percent of millennials, people born between 1980 and the year 2000,44 
support marijuana legalization.45 
While smoked marijuana is classified as a Schedule I narcotic,46 it has never 
been directly linked to any deaths.47  In order to be fatal, a marijuana user needs 
to consume an estimated 1,000 times the amount required to achieve the 
therapeutic/psychotropic effect on a single occasion.48  Many scientific 
authorities find substances like alcohol, tobacco, and prescription painkillers 
directly lead to more fatalities when they are abused.49  However, cannabis has 
increased in potency over the past few decades.50  Today’s cannabis user can 
achieve the same psychotropic effect with a smaller dosage than users in 
previous decades.51  Thus, cannabis users can consume less marijuana, and 
                                                                                                                   
 38 Thirty Years of America’s Drug War (PBS television broadcast 2000). 
 39 Id. 
 40 Id. 
 41 The Anti-Drug Abuse Act of 1986, 100 Stat. 3207 (1986); George Bush, President of the 
United States, Address to the Nation on the National Drug Control Strategy (Sept. 5, 1989). 
 42 For First Time, Americans Favor Legalizing Marijuana, http://www.gallup.com/poll/165539/fir 
st-time-americans-favor-legalizing-marijuana.aspx (last visited Nov. 15, 2015). 
 43 Id. 
 44 Millennial Definition, http://www.merriam-webster.com/dictionary/millennial (last visited 
Nov. 15, 2015). 
 45 Views of Same-Sex Marriage, Marijuana Legalization among Generations by Race (Mar. 5, 2014), 
http://www.pewsocialtrends.org/2014/03/07/millennials-in-adulthood/sdt-next-america-03-07-
2014-2-11/. 
 46 Controlled Substances Act, 21 U.S.C.S. § 801 (1970). 
 47 See Robert S. Gable, The Toxicity of Recreational Drugs, 94 AM. SCI., no. 3, 2006, at 206. 
 48 Id. 
 49 Id. 
 50 Marijuana: Know the Facts, http://www.whitehouse.gov/ondcp/ondcp-fact-sheets/marijuana-
know-the-facts (last visited Nov. 15, 2015). 
 51 Id. 
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ostensibly achieve the same psychotropic effect without any worry of a fatal 
overdose. 
However, cannabis consumption likely has harmful health consequences for 
the user.  Many drug policy authorities find that cannabis is most highly 
consumed by a small subset of users,52 who consume marijuana almost on a 
daily basis.53  Health authorities believe that a high rate of cannabis 
consumption leads to overstimulation of the endo cannabinoid system, resulting 
in addiction.54  Frequent users often experience withdrawal.55  Also, cannabis 
usage has been shown to have detrimental effects on the developing teenage 
brain.56  While cannabis usage among American ages twelve through seventeen 
has not increased over the past decade,57 marijuana usage in these 
developmental years has been linked to cognitive disorders, like paranoid 
schizophrenia.58 
Despite studies showing detrimental health impacts on chronic users and 
minors, cannabis could be a lucrative industry.  The cannabis plant “is 
America’s most valuable [cash crop], worth an estimated $35 billion, more than 
hay, soybeans, and corn.”59  Marijuana is estimated to potentially generate 
billions in both commercial and tax revenue.60  Investment in cannabis has 
increased from $500 million to a $7 billion industry in the past two years.61  
Additionally, by decriminalizing marijuana, both state and federal governments 
                                                                                                                   
 52 Market Size and Demand for Marijuana in Colorado, The Marijuana Policy Group, 18 (2014), 
https://www.colorado.gov/pacific/sites/default/files/Market%20Size%20and%20Demand%20
Study,%20July%209,%202014%5B1%5D.pdf. 
 53 Id. 
 54 Is Marijuana Addictive?, National Institute on Drug Abuse, https://www.drugabuse.gov/publ 
ications/research-reports/marijuana/marijuana-addictive (last visited Oct. 20, 2015). 
 55 Id. 
 56 Krista M. Lisdahl et al., Dare to delay?  The impacts of adolescent alcohol and marijuana use onset on 
cognition, brain structure, and function, http://journal.frontiersin.org/Journal/10.3389/fpsyt.2013.000 
53/full (last visited Nov. 15, 2015). 
 57 National survey shows lower rate of illicit drug use among adolescents ages 12 to 17, http://www.samhsa. 
gov/newsroom/press-announcements/201409160400 (last visited Nov. 15, 2015). 
 58 David Bienenstock, The Clinic: A Surprising Link between Marijuana and Schizophrenia, http:// 
www.hightimes.com/read/clinic-surprising-link-between-marijuana-and-schizophrenia (last visited 
Nov. 15, 2015). 
 59 Adrian A. Ohmer, Investing in Cannabis: Inconsistent Government Regulation and Constraints on 
Capital, 3 MICH. J. PRIVATE EQUITY & VENTURE CAPITAL L. 97 (2013) (quoting GREG CAMPBELL, 
POT, INC.: INSIDE MEDICAL MARIJUANA, AMERICA’S MOST OUTLAW INDUSTRY, at xxiii (2012)) 
(internal quotations omitted). 
 60 Jeffery A. Miron, Milton Friedman, 500+ Economists Call for a Marijuana Debate, http://www. 
prohibitioncosts.org (last visited Sept. 28, 2014). 
 61 Meet the Financier behind a Hot Pot Stock, http://www.bloomberg.com/news/2014-06-18/lega 
l-pot-sets-off-penny-stock-frenzy.html (last visited Nov. 15, 2015). 
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stand to save billions from law enforcement costs.62  Cannabis is the most 
common drug seized at the U.S. border, totaling almost 2 million pounds a 
year.63  Further, the federal “drug interdiction budget request for F[iscal] Y[ear] 
2011 was . . . $15.55 billion, a 3.5 percent increase from F[iscal] Y[ear]  2010.”64  
Legalizing cannabis entirely would eliminate border seizure and enforcement 
costs for marijuana from the federal budget. 
B.  THE CANNABIS PLANT, PSYCHOTROPIC EFFECTS, AND THE GROWTH 
PROCESS 
Cannabis has three species: cannabis sativa, cannabis indica, and cannabis 
ruderalis.65  These species contain compounds called cannabinoids, including 
tetrahydrocannibinol (THC), which is the primary psychoactive ingredient that 
alters cognitive functioning.66  Depending upon the manner of consumption, 
THC and other cannabinoids from the cannabis plant may cause a variety of 
effects on the user, including euphoria, increased giggling, lethargy, and 
paranoia, among others.67  
Reproduction of the cannabis plant occurs either asexually or sexually.68  
Asexual reproduction occurs through plant cloning.69  For example, a grower 
can take a cutting from the cannabis plant and root it in a contained body of 
water known as hydroponics.70  Asexually reproduced cannabis offspring are 
genetically identical to the parent plant.71  Conversely, sexual reproduction is the 
fusion of gametes between a male and a female plant that results in a seed.72  
The offspring will have different physical and genetic characteristics due to the 
                                                                                                                   
 62 Jeffery A. Miron, The Budgetary Implications of Drug Prohibition, Department of Economics, 
Harvard University (2010), http://scholar.harvard.edu/files/miron/files/budget_2010_final_0. 
pdf. 
 63 Marijuana Seizures along the U.S. Mexico Border, http://static.apps.cironline.org/border-
seizures/ (last visited Nov. 15, 2015). 
 64 Ohmer, supra note 59, at 97–98 (citations omitted). 
 65 GEOFFREY GUY ET AL., THE MEDICINAL USES OF CANNABIS AND CANNABINOIDS 74 
(Pharmaceutical Press, 2004). 
 66 Amresh Shrivastava et al., Cannabis Use and Cognitive Dysfunction, INDIAN J. PSYCHIATRY, 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3221171 (last visited Nov. 15, 2015). 
 67 Id. 
 68 R.C. Clarke, Cannabis Botany, WEED FARMER, http://www.weedfarmer.com/cannabis/bot 
any_guide.php (last visited Oct. 18, 2015). 
 69 BUY DUTCH SEEDS, http://www.buydutchseeds.com/growing-guide/cloning-cannabis (last 
visited Nov. 15, 2015). 
 70 Id. 
 71 Id. 
 72 Clarke, supra note 68. 
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recombination of chromosomes.73  Sexual reproduction between a male and 
female cannabis plant leads to new cannabis varieties.74 
The marijuana product differs in its physical structure, aroma, and 
psychotropic effect and potency based on the growing conditions and 
harvesting method.75  Cannabis is grown either in soil with natural nutrients, or 
through hydroponics, a method that uses inorganic content like rock wool or 
clay pellets.76  During the maturation process, growers can manipulate the onset 
of the flowering period by limiting the amount of sunlight and darkness the 
plant receives.77  Once the flowering period starts, the unfertilized female part 
of the cannabis plant, known as the pistil, is harvested, dried, and cured.78  The 
timing of the harvest can change the psychotropic effect.79  The finished 
product is a floral cluster, commonly known as the “bud.”80  The “bud” is the 
ingestible end-product of the cannabis growing cycle.  It can be packaged by 
retailers and enjoyed by consumers. 
C.  THE FEDERAL BAN ON CANNABIS 
Under the Controlled Substances Act of 1970, possession, production, 
cultivation, and distribution of marijuana is prohibited.81  The executive branch of 
the United States charges the Drug Enforcement Administration (DEA) with the 
enforcement of the CSA.  The DEA classifies drugs according to the “drug’s 
acceptable medical use and the drug’s abuse or dependency potential.”82  Again, 
cannabis is classified as a Schedule I drug, among other drugs including “heroin, 
lysergic acid diethylamide (LSD), . . . methylenedioxymethamphetamine (ecstasy), 
                                                                                                                   
 73 Id. 
 74 Id. 
 75 Id. 
 76 THE DAILY SMOKER, http://www.dailysmoker.com/cannabis-grow-guide/conditions/med 
ium (last visited Nov. 15, 2015). 
 77 Cannabis Life Cycle, MONTANA LEGISLATURE: CHILDREN, FAMILIES, HEALTH, AND HUMAN 
SERVICES INTERIM COMMITTEE (June 2009–2010), http://leg.mt.gov/content/Committees/Inter 
im/2009_2010/Children_Family/Emerging-Issue/mmga-presentation-cannabis-life-cycle.pdf. 
 78 Clarke, supra note 68. 
 79 Id.  Depending on the point of harvest, the psychoactive effect can be a “light cerebral 
high,” or an “intense body effect.”  This means a cannabis grower can vary the effect of their 
product to suit different consumers. 
 80 Id. 
 81 21 U.S.C. § 841. 
 82 Drug Scheduling, DRUG ENFORCEMENT AGENCY, http://www.justice.gov/dea/druginfo/ds. 
shtml (last visited Nov. 15, 2015). 
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methaqualone, and peyote.”83  The federal government imposes severe 
punishments on those who possess, produce, or distribute cannabis.84 
Under the CSA, an interested party can change a drug’s schedule through an 
administrative mechanism.85  Under this mechanism, an interested party can 
initiate a process to add, delete, or change the schedule of a controlled 
substance.86  National Organization for the Reform of Marijuana Laws, 
otherwise known as NORML, and other organizations invoked this 
administrative mechanism in 1972 to change the classification of cannabis.87  
After sixteen years of court proceedings and negotiations, Administrative Law 
Judge Francis L. Young issued a decision.88  His opinion discussed three issues: 
one principal issue and two subsidiary issues.89  The principal issue concerned 
“whether the marijuana plant, considered as a whole, may lawfully be 
transferred from Schedule I to Schedule II.”90  The two subsidiary issues 
regarded “whether [cannabis] . . . has an accepted medical use in treatment in 
the United States”91 and “whether there is a lack of accepted safety use of the 
marijuana plant under medical supervision.”92 
After thirty-eight findings of fact,93 Judge Young found, by a preponderance 
of the evidence, that cannabis has “an accepted medical use in treatment in the 
United States in effecting relief for cancer patients.”94  In assessing the safety of 
cannabis use, Judge Young found “no record in . . . extensive medical literature 
describing a proven, documented cannabis-induced fatality.”95  While the DEA 
argued it needed more studies and tests to determine if cannabis can be 
consumed safely, Judge Young found “it is unrealistic and unreasonable to 
require unanimity of [medical professional] opinion[s]”96 on the issue of safety.  
                                                                                                                   
 83 Id. 
 84 See 21 U.S.C. § 841 (2012).  The penalty for trafficking of 50 kilograms of marijuana or 10 
kilograms of hashish is not more than five years imprisonment and a fine up to $250,000. 
 85 Id. § 814. 
 86 Ohmer, supra note 59, at 100–01 (citing 21 U.S.C. § 814). 
 87 Id. at 101. 
 88 Id. 
 89 Marijuana Rescheduling Petition, Dep’t of Justice, Drug Enforcement Admin., No. 86-22, at 
7 (Sept. 6, 1988). 
 90 Id. 
 91 Id. 
 92 Id. 
 93 Id. at 10–26. 
 94 Id. at 34. 
 95 Id. at 56. 
 96 Id. at 66. 
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Judge Young concluded “the provisions of the [CSA] permit and require the 
transfer of marijuana from Schedule I to Schedule II.”97 
Despite Judge Young’s ruling, the DEA denied a petition to change 
cannabis to a Schedule II drug following the administrative opinion.98  The 
DEA issued the following statement: 
The Administrator rejects the administrative law judge’s findings 
and conclusions.  They were erroneous; they were not based 
upon credible evidence; nor were they based upon evidence in 
the record as a whole.  Therefore, in this case, they carry no 
weight and do not represent the position of the agency or its 
Administrator.99 
The D.C. Circuit Court of Appeals affirmed the decision of the DEA and 
subsequently denied the petitioners’ petition for review.100   As a result of this 
denial, cannabis remains a Schedule I controlled substance. 
D.  STATE LEGALIZATION OF CANNABIS FOR MEDICAL AND RECREATIONAL 
USE 
Justice Brandeis once said, 
It is one of the happy incidents of the federal system that a single 
courageous state may, if its citizens choose, serve as a laboratory; 
and try novel social and economic experiments without risk to 
the rest of the country.  This Court has the power to prevent an 
experiment.101 
This famous statement likely provided the foundation for novel state legislation 
in the area of cannabis.  The first experiment came in California in 1996, which 
legalized cannabis for medical purposes.102  A bevy of states then followed 
                                                                                                                   
 97 Id. at 67. 
 98 Marijuana Scheduling Petition; Denial of Petition, 54 Fed. Reg. 53,767, 53,783 (Dep’t of 
Justice, Drug Enforcement Admin., Dec. 29, 1989). 
 99 Id. 
 100 Ohmer, supra note 59, at 102. 
 101 New State Ice Co. v. Liebmann, 285 U.S. 262, 311 (1932) (Brandeis, J., dissenting) 
(explaining that states have agency to enact laws in novel areas of law). 
 102 Ohmer, supra note 59, at 102. 
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California’s lead.103  These states have removed criminal consequences for 
possession, production, and use as long as a doctor has recommended use for 
medical issues.104 
Although state legislation has sanctioned cultivation and possession of 
cannabis within its borders, the federal government reserves the power to 
regulate interstate cannabis.  In 2005, the Supreme Court upheld Congress’s 
power to regulate marijuana under the interstate Commerce Clause in Gonzales 
v. Raich.105  Here, California passed Proposition 215, which was codified as the 
Compassionate Use Act of 1996.106  The Act allowed ill patients to have access 
to marijuana for medicinal purposes.107  Also, the Act created an exemption to 
criminal prosecution for doctors and allowed patients and caregivers to grow 
marijuana with a prescription.108  
The Court of Appeals for the Ninth Circuit reversed the district court and 
held that homegrown medical marijuana was a “separate and distinct class of 
activities”109 beyond the reach of federal power.110  In an application of the 
aggregation theory under Wickard v. Filburn,111 the United States Supreme Court 
found the application of the Controlled Substances Act to intrastate growers is 
within the reach of Federal regulation because Congress has the power to 
regulate even intrastate cannabis activities that substantially affect interstate 
commerce.112  In analogizing marijuana in this case to wheat production in 
Wickard, the Court found the purpose of the CSA was to regulate the supply of 
controlled substances into the drug market.113  Subsequently, the Court found 
                                                                                                                   
 103 Id. at 102–03.  Other states that legalized cannabis for medical use include Oregon (1998); 
Alaska (1998); Washington (1998); Maine (1999); Hawaii (2000); Colorado (2000); Nevada (2000); 
Vermont (2004); Montana (2004); Rhode Island (2006); New Mexico (2007); Michigan (2008); 
Arizona (2010); New Jersey (2010); Delaware (2011); Connecticut (2012); Massachusetts (2012); 
Illinois (2013); New Hampshire (2013); Maryland (2014); Minnesota (2014); and New York 
(2014).  States with limited access to Medical Marijuana include Alabama, Florida, Georgia, Iowa, 
Kentucky, Louisiana, Mississippi, Missouri, Oklahoma, South Carolina, Tennessee, Texas, Utah, 
Virginia, Wisconsin, and Wyoming.  State Medical Marijuana Laws, National Conference of State 
Legislatures, http://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx (last visited 
Oct. 20, 2015). 
 104 Ohmer, supra note 59, at 103. 
 105 545 U.S. 1 (2005). 
 106 Id. at 5. 
 107 Id. 
 108 Id. 
 109 Raich v. Ashcroft, 352 F.3d 1222, 1228 (2003). 
 110 Id. at 1228. 
 111 See 317 U.S. 111 (1942). 
 112 Gonzales, 545 U.S. at 17. 
 113 Id. at 19. 
13
Summer: Patenting Marijuana Strains: Baking Up Patent Protection for Grow
Published by Digital Commons @ Georgia Law, 2015
182 J. INTELL. PROP. L.  [Vol. 23:169 
 
 
there was a rational basis for Congress to believe that leaving homegrown 
marijuana outside the CSA would have an effect on drug markets when viewed 
in the aggregate.114  Further, the Court stated the CSA is a constitutionally valid 
statutory scheme and that Congress had the power to make all laws necessary 
and proper to enforce the CSA when it enacted the CSA.115 
Even though the majority conceded that marijuana has a beneficial 
medicinal purpose, it found the federal government can criminalize marijuana 
under the CSA for any purpose.116  In his opinion, Justice Stevens suggested 
that if federal regulation on medical marijuana is “beyond the ‘outer limits’ of 
Congress’ Commerce Clause authority,”117 then “marijuana . . . for recreational 
purposes is also beyond those ‘outer limits,’ whether or not a State elects to 
authorize or even regulate such use.”118 
Furthermore, in upholding the application of the CSA to intrastate activities, 
Justice Stevens invoked the Supremacy Clause by reiterating, “that if there is 
any conflict between federal and state law, federal law shall prevail.”119  Even 
though respondents in this case were comporting with the California regulatory 
scheme, respondents were not beyond federal jurisdiction under the CSA.120 
In dicta, Justice Stevens commented that medical discretion to prescribe 
marijuana was “open-ended.”121  Thus, doctors could prescribe cannabis for 
recreational uses and increase the supply of marijuana into drug markets.122 
Despite the Gonzales decision, California maintained its state law permitting 
medical marijuana.  However, this decision created a legal quandary for 
dispensaries in California and other states sanctioning medical marijuana.  While 
homegrown marijuana was permitted for sick patients under state law, cannabis 
cultivators could still be arrested and prosecuted by the federal government 
under the CSA.123 
                                                                                                                   
 114 Id. 
 115 Id. at 22.  Congress has the power “[t]o make all Laws which shall be necessary and proper 
for carrying into Execution the foregoing Powers, and all other Powers vested by this 
Constitution in the Government of the United States, or in any Department or Officer thereof.” 
U.S. CONST. art. I, § 8, cl. 18. 
 116 Gonzales, 545 U.S. at 27. 
 117 Id. at 28. 
 118 Id. 
 119 Id. at 29. 
 120 Id. 
 121 Id. at 30–31. 
 122 Id. at 31. 
 123 Id. 
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Nevertheless, Colorado and Washington legalized marijuana for recreational 
use in 2013.124  In Colorado, the state legalized marijuana through amendments 
to its constitution, “[i]n the interest of the efficient use of law enforcement 
resources, enhancing revenue for public purposes, and individual freedom.”125  
As long as a person is over the age of twenty-one, he or she will be legally 
allowed to consume marijuana, subject to certain restrictions.126  Additionally, 
said person can possess six cannabis plants.127  
The state constitutional provision regulates marijuana in a manner consistent 
with alcohol.128  Production and cultivation for commercial use requires a 
license from the state.129  The provision defines a “marijuana establishment” for 
recreational use under four different types: “a marijuana cultivation facility, a 
marijuana testing facility, marijuana product manufacturing facility, or a retail 
marijuana store.”130  These definitions essentially define the supply chain of 
marijuana distribution.  Under the provision, a cultivation facility is the only 
“entity licensed to cultivate, prepare, package, and sell marijuana” to other 
facilities, but it cannot sell directly to the consumer.  Only a retail store can sell 
to the consumer.131  The product manufacturing facility cannot cultivate 
marijuana; it can only package and prepare the product for retailers.132  The 
separation of entities allows Colorado to regulate the flow of marijuana from 
producer to consumer and prohibit wholesale distribution directly to the 
consumer. 
In Washington, voters approved Initiative Measure No. 502, which 
“intend[s] to stop treating adult marijuana use as a crime.”133  Initiative 502 is 
similar to the Colorado constitutional provision with immaterial changes in 
terminology.  The procedures to obtain a marijuana license are explicitly 
                                                                                                                   
 124 See COLO. CONST. art. XVIII, § 16 (2013); WASH. ADMIN. CODE §§ 314-55-005 through 314-
55-540 (2013).  As of November 5th, 2014, Oregon, Alaska, and the District of Columbia have 
legalized recreational marijuana. 
 125 COLO. CONST. art. XVIII, § 16(1)(a). 
 126 Id.  These certain restrictions include driving under the influence of marijuana, giving 
marijuana to a minor, requiring employers to permit use of marijuana in employment contracts, 
and other issues concerning the control of property.  Id. § 16(6). 
 127 Id. § 16(3)(b). 
 128 Id. § 16(1)(b). 
 129 Id. § 16(4)(c).  This is subject to “article 4 of title 24 of the Colorado Administrative 
Procedure Act or any successor provision.”  Id. § 16(5)(a)(1). 
 130 Id. § 16(2)(i). 
 131 Id. § 16(2)(n). 
 132 Id. § 16(2)(j). 
 133 Initiative Measure No. 502, http://sos.wa.gov/_assets/elections/initiatives/i502.pdf (last 
visited Nov. 15, 2015). 
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codified in Washington’s Administrative Code.134  Like Colorado, Washington 
regulates marijuana similarly to alcohol under its Liquor Control Board.135  One 
material difference from Colorado is that Initiative 502 intends for tax revenue 
to fund “education, health care, research, and substance abuse prevention.”136  
In Colorado, tax revenue from cannabis will go to school construction 
projects.137 
While Colorado and Washington have enacted liberal marijuana legislation 
in the face of the Gonzales decision, persons exercising rights afforded by 
Colorado and Washington are still subject to federal prohibitions.138  Thus, the 
federal government may exercise prosecutorial discretion to enforce the CSA.139  
This means that growers may face federal criminal prosecution, even though 
recreational cannabis is legal in their state. 
E.  THE UNITED STATES DEPARTMENT OF JUSTICE’S PROSECUTORIAL 
DISCRETION TO ENFORCE THE CONTROLLED SUBSTANCES ACT 
Despite state legalization, the federal government can circumvent state law 
and enforce the Controlled Substances Act.  The power to enforce the CSA 
comes from the President of the United States, who has the power to execute 
federal laws.140  The Department of Justice is the extension of this presidential 
power, headed by the Attorney General.141 
Under former U.S. Attorney General Eric Holder,142 the Department of 
Justice issued press releases giving guidance for marijuana drug enforcement in 
states where marijuana has been legalized.143  In a memorandum released on 
August 29, 2013, the Department of Justice stated: 
 Accordingly, in exercising prosecutorial discretion, prosecutors 
should not consider the size or commercial nature of a marijuana 
operation alone as a proxy for assessing whether marijuana 
                                                                                                                   
 134 See WASH. ADMIN. CODE §§ 314-55-005 through 314-55-540 (2013). 
 135 See supra note 124 and accompanying text. 
 136 See supra note 124 and accompanying text. 
 137 COLO. CONST. art. XVIII, § 16(5)(d). 
 138 Gonzales, 545 U.S. at 29. 
 139 Id. 
 140 U.S. CONST. art. II. 
 141 28 U.S.C. § 503. 
 142 Holder announced his resignation on September 25, 2013.  Attorney General Eric Holder 
Announces Resignation, http://www.cnn.com/2014/09/25/politics/eric-holder-resignation/ (last 
visited Nov. 15, 2015).  He was succeeded by Loretta E. Lynch. 
 143 James M. Cole, Guidance Regarding Marijuana Enforcement, Department of Justice (2013), 
http://www.justice.gov/iso/opa/resources/3052013829132756857467.pdf. 
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trafficking implicates the Department’s enforcement 
priorities . . . Rather, prosecutors should continue to review 
marijuana cases on a case-by-case basis and weigh all available 
information and evidence, including, but not limited to, whether 
the operation is demonstrably in compliance with a strong and 
effective state regulatory system.144  
While not totally eliminating its ability to enforce the CSA against state 
dispensaries, the Department of Justice has effectively relaxed its role in 
prosecuting state cannabis business entities comporting with a state regulatory 
scheme.145  Further, Department of Justice officials stated, “While the 
prosecution of drug traffickers remains an important priority, the president and 
the administration believe that targeting individual marijuana users, especially 
those with serious illnesses and their caregivers, is not the best allocation of 
federal law enforcement resources.”146 
However, in the same memorandum, the Department of Justice made clear 
that it retains the right to enforcement in many scenarios.147  While 
prosecutorial discretion has relaxed, the Department of Justice remains vague 
on which specific cases it will prosecute.  In other words, some prosecutors 
may still raid dispensaries that comport with state regulatory schemes, despite 
the memorandum.  The effect of this memo on those applying for cannabis 
variety patents is unclear and speculative at best. 
                                                                                                                   
 144 Id. 
 145 Justice Department Announces Update to Marijuana Enforcement Policy, United States Department 
of Justice (2013), http://www.justice.gov/opa/pr/justice-departmentannounces-update-marijuan 
a-enforcement-policy (arguing that federal government’s limited prosecutorial resources should 
be utilized on enforcement priorities and leave state and local law enforcement agencies to handle 
intrastate and local marijuana activity). 
 146 Nicole Flatow, BREAKING: Justice Department Won’t Challenge State Marijuana Laws, Announces 
Major Shift In Law Enforcement Policy, THINK PROGRESS, http://thinkprogress.org/justice/2013/ 
08/29/2551851/breaking-justice-department-wont-challenge-state-marijuana-laws-announces-ma 
jor-shift-law-enforcement-policy/ (last visited Nov. 15, 2015). 
 147 Cole, supra note 143, at 1–2.  The memorandum sets out situations where enforcement is a 
priority, including preventing the distribution of marijuana to minors, the sale of marijuana from 
going to criminal enterprises, gangs, and cartels, the diversion of marijuana to states where it is 
legal under state law in some form to other states, state-authorized marijuana activity from being 
used as a cover or pretext for the trafficking of other illegal drugs or other illegal activity, violence 
and firearms in the cultivation and distribution of marijuana, drugged driving and exacerbation of 
other adverse public health consequences associated with marijuana use, the growing or marijuana 
on public lands and the attendant public safety and environmental dangers posed by marijuana 
production on public lands, and marijuana possession or use on federal property.  
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In a farewell interview with the press, Eric Holder discussed rescheduling 
marijuana by questioning, “whether or not marijuana is as serious a drug as is 
heroin.”148  He further stated, “The question of whether or not they should be 
in the same category is something that I think we need to ask ourselves, and use 
science as the basis for making that determination.”149  
While dialogue and discussions indicate changing politics and enforcement 
policy, cannabis cultivation is still a prosecutable defense under the CSA.150  
True change in this area of law can only be changed by congressional legislation 
or rescheduling cannabis from Schedule I. 
F.  THE LEGAL ENVIRONMENT BEHIND UTILITY AND PLANT PATENTS 
The United States Constitution explicitly provides for patents.151  The 
pertinent section states, “[t]o promote the [p]rogress of [s]cience and useful 
[a]rts, by securing for . . . [i]nventors the exclusive [r]ight to their respective 
[w]ritings and [d]iscoveries.”152  The underlying rationale for this constitutional 
provision is an economic incentives theory.153  By providing a limited monopoly 
to inventors, patents encourage invention and innovation of works of utilitarian 
value to the public interest.154  Adam Smith argued for “the need for limited 
monopolies to promote innovation and commerce requiring substantial up-
front investments and risk.”155  Another famous economist, John Stuart Mill, 
found “a temporary ‘exclusive privilege’ was preferable to general governmental 
awards on the ground that it avoided ‘discretion’ and ensured that the reward to 
the inventor was proportional to the ‘usefulness’ to consumers of the 
invention.”156  If patents extend to the cannabis industry, a grower will likely 
want to capitalize on his or her strain of cannabis by monopolizing it.  This may 
give the necessary spark needed to see rapid innovations in cannabis varieties. 
                                                                                                                   
 148 Interview by Katie Couric with Eric Holder, U.S. Attorney General (Sept. 25, 2014), http:// 
news.yahoo.com/video/holder-disproportionately-longer-prison-sentences-053241539.html. 
 149 Id. 
 150 21 U.S.C. § 841 (2010). 
 151 U.S. CONST. art. I, § 8, cl. 8. 
 152 Id. 
 153 Michael A. Sartori, An Economic Incentives Analysis of the Jury’s Role in Patent Litigation, 79 J. PAT. 
& TRADEMARK OFF. SOC’Y 331, 336 (1997) (discussing the economic incentives theory in patent 
law). 
 154 Id. at 339. 
 155 Peter Menhall, Intellectual Property: General Theories 131 (1991), available at http://levine.sscnet. 
ucla.edu/archive/ittheory.pdf. 
 156 Id. at 132. 
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Patent issues, from application to infringement, are exclusively within 
federal jurisdiction.157  Applications for patents are reviewed by a federal agency 
known as the United States Patent and Trademark Office (USPTO).158  The 
Federal Circuit is a special court that receives appeals of patent cases.159 
A cannabis cultivator could protect his or her cannabis strain through a 
utility patent,160 the Plant Patent Act161 (PPA), or the Plant Variety Protection 
Act162 (PVPA).  Utility patents are governed by 35 U.S.C. § 101,163 which states, 
“[w]hoever invents or discovers any new and useful process, machine, 
manufacture, or composition of matter, or any new and useful improvement 
thereof, may obtain a patent therefor, subject to the conditions and 
requirements of this title.”164  Abstract ideas, physical phenomena, and laws of 
nature, including compounds naturally occurring in nature, are not 
patentable.165  Utility patents must satisfy four elements: novel, statutory, useful, 
and nonobvious.166 
To receive a patent, an invention or innovation must be novel.167  Per 35 
U.S.C. § 102, an invention cannot be patented if “the claimed invention was 
patented, described in a printed publication, or in public use, on sale, or 
otherwise available to the public before the effective filing date of the claimed 
invention”168 or “the claimed invention was described in a patent . . . or in an 
application for patent published . . . in which the patent . . . names another 
inventor and was . . . filed before the . . . filing date.”169  Likewise, under 
§ 102(b), an invention is ineligible for patent protection where public use of the 
invention, prior to applying for a patent, has led people to believe that the 
invention is available to all.170  This requirement protects the public’s 
expectations while also encouraging prompt disclosure of new and useful 
                                                                                                                   
 157 Mark J. Henry, State Courts Hearing Patent Cases: A Cry for Help to the Federal Circuit, 101 DICK. 
L. REV. 41, 44 (1996). 
 158 Note, The Disclosure Function of the Patent System (Or Lack Thereof), 118 HARV. L. REV. 2007, 
2009 (2005). 
 159 Id. at 2011–12. 
 160 35 U.S.C. § 101 (2012). 
 161 Townsend-Purnell Plant Patent Act, 35 U.S.C. §§ 161–164 (1954). 
 162 See 7 U.S.C.A. §§ 2321–2582 (2015). 
 163 35 U.S.C. § 101 (2012). 
 164 Id. 
 165 David Tyler, Patent Requirement, BITLAW, http://bitlaw.com/patent/requirements.html (last 
visited Nov. 15, 2015). 
 166 Id. 
 167 Id. 
 168 35 U.S.C. § 102(a)(1) (2012). 
 169 Id. § 102(a)(2). 
 170 See Tyler, supra note 165. 
19
Summer: Patenting Marijuana Strains: Baking Up Patent Protection for Grow
Published by Digital Commons @ Georgia Law, 2015
188 J. INTELL. PROP. L.  [Vol. 23:169 
 
 
information.171  This requirement is similar to the novelty requirement, except it 
looks backward from the date of application rather than the date of 
invention.172 
The “useful” requirement is easily satisfied if the invention under the patent 
statute has any utilitarian purpose.173  Many courts have found that the term 
“useful” in the patent statute is laden with ambiguity.174  A patent discharges the 
obligation of usefulness if it sets forth a specific and substantial utility.175  
Specific utility is defined by specificity to the subject matter claimed176 and can 
“provide a well-defined and particular benefit to the public.”177  Substantial 
utility in “[a patent] application must show that an invention is useful to the 
public as disclosed in its current form, not that it may prove useful at some 
future date after further research.”178  But, a court is more likely to find an 
invention or innovation is not useful if it is an inoperative invention, meaning it 
does not operate to produce the results claimed by the patent applicant.179  As 
long as the invention or innovation operates as stated in the patent application 
and satisfies a specific and substantial utility, the standard for usefulness is 
usually met in patent applications. 
Finally, under 35 U.S.C. § 103,  
[a] patent for a[n] invention may not be obtained . . . if the 
differences between the claimed invention and the prior art are 
such that the claimed invention . . . would have been obvious 
before the effective filing date . . . to a person having ordinary 
skill in the art.180 
The nonobvious requirement is the most difficult barrier to a utility patent.  In a 
nonobvious determination, patent examiners will review previous patents to 
                                                                                                                   
 171 Id. 
 172 Id. 
 173 Id.  This will be explored in greater detail in Part II.G. 
 174 Brenner v. Manson, 383 U.S. 519, 529 (1966) (simply everyday word like “useful” can be 
“pregnant with ambiguity when applied to the facts of life”). 
 175 2107.01 General Principles Governing Utility Rejections (R-11.2013), United States Patent and 
Trademark Office (Mar. 27, 2014, 10:10 AM), http://www.uspto.gov/web/offices/pac/mpep/ 
s2107.html. 
 176 Id. 
 177 In re Fisher, 421 F.3d 1365, 1371 (Fed. Cir. 2005). 
 178 Id. at 1371. 
 179 2107.01 General Principles Governing Utility Rejections (R-11.2013), supra note 175.  In re 
Harwood, 390 F.2d 985, 989, 156 U.S.P.Q. 673, 676 (C.C.P.A. 1968) (“An inoperative invention, 
of course, does not satisfy the requirement of 35 U.S.C. § 101 that an invention be useful.”). 
 180 35 U.S.C. § 103 (2012). 
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find similarities to the claimed invention.181  If all the features from the claimed 
invention can be found in a single patent, then it will be rejected.  Otherwise, 
the examiner will combine two or more patents and attempt to find all the 
claimed invention’s features in the combined patents.182  If the examiner 
successfully finds all the features through a combination of patents, the patent 
examiner will reject the claimed invention because it is an obvious combination 
of features in the prior art.183  If the claimed invention overcomes the patent 
examiner’s process, then it will fulfill this element. 
Besides a utility patent, a cannabis cultivator could get a plant patent under 
the PPA.  The PPA became law in 1930.184  It was the first legislation in the 
world to afford patent rights to plant breeders and ensure protection for 
innovators in agriculture.185  The statute states “whoever invents or discovers 
and asexually reproduces any distinct and new variety of plant, including 
cultivated sports, mutants, hybrids, and newly found seedlings . . . may obtain a 
patent therefor.”186  Many courts interpret the phrase “invents or discovers”187 
to mean “uniqueness of the plant and subsequent asexual reproduction of the 
plant.”188  In order to comport with the phrase ‘asexual reproduction’ in the 
Act, courts deem acceptable methods of reproduction to be “grafting, budding, 
cutting, layering, division, and the like.”189  The Act recognizes the plant 
breeder’s work “in aid of nature” should be granted patent protection.190  In 
subsequent years, Congress further addressed plant patents in general patent 
law.191  It changed the protections for plant patents from the “ ‘exclusive right’ 
to the ‘right to exclude,’ based on court interpretations of the right conferred to 
utility patents.”192  Later on, Congress disallowed patent protection for plants in 
an uncultivated state.193  As a result, plants in a cultivated, fully-formed state 
                                                                                                                   
 181 See Tyler, supra note 165. 
 182 Id. 
 183 Id. 
 184 Ann K. Wooster, Annotation, Construction and Application of Plant Patent Act (35 U.S.C.A. 
§§ 161 et seq.), 135 A.L.R. FED. 273 (1996). 
 185 Id. 
 186 35 U.S.C. § 161 (2012). 
 187 Id. 
 188 Wooster, supra note 184, § 2, at 282. 
 189 Id. 
 190 Id. 
 191 Id. (citing the Act of July 19, 1952 ch. 950, 66 Stat. 804). 
 192 Id. 
 193 Id.  Uncultivated plant varieties are “wild varieties discovered by [a] plant explorer or other 
person who has in no way engaged either in plant cultivation or care and who has in no other way 
facilitated nature in the creation of a new and desirable variety.”  S. REP. NO. 71-315, at 3 (1930). 
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and later asexually reproduced were given more expanded protections.194  The 
PPA limits asexual reproduction to that of one mother plant.195  In 1995, the 
Federal Circuit reaffirmed in Imazio Nursery, Inc. v. Dania Greenhouse that only 
asexual reproduction from one mother plant is protected under the PPA.196 
In 1970, Congress sought to expand plant protections by passing the 
PVPA.197  Unlike the PPA, the PVPA affords “patent-like protections to novel 
varieties of sexually reproduced plants.”198  Thus, seeds and other forms of 
uncultivated, sexually reproduced plants, specifically removed from the PPA, can 
receive patent-like protections.199  The patent-like protections include “exclud[ing] 
others from selling the variety, . . . offering it for sale, . . . reproducing 
it, . . . importing it, . . . exporting it, or using it [to] produc[e] (as distinguished 
from developing) a hybrid or different variety therefrom” for a period of twenty 
years.200  The purpose of the PVPA is to provide developers of novel plant 
varieties with “adequate encouragement for research, and for marketing when 
appropriate, to yield for the public the benefits of new varieties.”201  Subsequent 
amendments to the PVPA require that the plant variety be “new, distinct, 
uniform, and stable.”202  Thus, the PVPA would protect a sexually reproduced 
plant from distinct male and female plants, but not a clone grown from a cutting 
of a single mother plant. 
However, protection for plants patented under PVPA do not originate from 
the USPTO.  Rather, this protection comes from the Department of 
Agriculture.203  Therefore, PVPA protections are patent-like, but are not true 
patents in themselves.  Thus, PVP certificates are less protective of legal rights 
than utility and plant patents because they are not regulated and enforced with 
the USPTO’s expertise. 
The Federal Circuit and the United States Supreme Court have not 
addressed whether marijuana strains are patentable.  However, case law 
involving corn serves as guidance in this area by analogy.  The Supreme Court 
upheld the patentability of sexually reproduced plants in J.E.M. Ag Supply v. 
Pioneer Hi-Bred International, Inc. in 2001 (Pioneer).  Pioneer Hi-Bred International 
                                                                                                                   
 194 Wooster, supra note 184. at 282. 
 195 Id. § 9. 
 196 Id. § 5, at 287 (citing Imazio Nursery, Inc. v. Dania Greenhouse, 69 F.3d 1560 (Fed. Cir. 
1995)). 
 197 Id. at 343. 
 198 Id. § 2, at 282. 
 199 Id. 
 200 See 7 U.S.C.A. § 2483 (1970). 
 201 See id. § 2581. 
 202 Wooster, supra note 184. 
 203 7 U.S.C.A. § 2321 (1970). 
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was a corporation selling seeds from its hybrid corn plant 3394.204  Pioneer sold 
the seeds under a license that did not allow “the use of such seed or the 
progeny thereof for propagation or seed multiplication or for production or 
development of a hybrid or different variety of seed.”205  The petitioner, J.E.M. 
Ag Supply (J.E.M.) doing business as Farm Advantage, purchased these seeds 
from Pioneer in bags with the license agreement.206  J.E.M. resold the bags, and 
was subsequently sued by Pioneer, which claimed patent infringement.207  
J.E.M. entered a counterclaim of patent invalidity stating that sexually-
reproduced plants are not patentable subject matter under 35 U.S.C. § 101.208  
The Supreme Court affirmed the judgments of the district court and court of 
appeals, which granted summary judgment to Pioneer.209 
In Pioneer, the Supreme Court cited Diamond v. Chakrabarty,210 which found 
that § 101 of the patent statute should be broadly interpreted.211  The 
Chakrabarty Court found that Congress does not need to expressly authorize 
protection of a particular patentable subject matter.212  Prior to passage of the 
PPA in 1930, the Chakrabarty Court explained that two factors precluded plants 
from patentability.213  First, plants were believed to be products of nature, and 
thus, not patentable subject-matter.214  Second, plants could not fulfill the 
description requirement in patent law.215  While Congress did not believe plants 
were patentable prior to 1930, the Chakrabarty Court found “the relevant 
distinction was not between living and inanimate things, but between products 
of nature . . . and human-made inventions.”216  After the Chakrabarty decision, 
the USPTO found that plants are patentable subject matter under § 101 because 
they fall within the meaning of “manufacture” or “composition of matter” as 
used in the statute.217  Thus, a plant patent may achieve the status of a utility 
patent. 
                                                                                                                   
 204 J.E.M. Ag Supply, Inc. v. Pioneer Hi-Bred International, Inc., 534 U.S. 124 (2001).  The 
patent for this seed is U.S. Patent No. 5,491,295, cols. 2–3, at 29–30. 
 205 Pioneer, 534 U.S. at 128 (quoting U.S. Patent No. 5,491,295 at 51). 
 206 Id. 
 207 Id. 
 208 Id. at 129. 
 209 Id. at 129–30. 
 210 447 U.S. 303 (1980). 
 211 Pioneer, 534 U.S. at 130. 
 212 Id. 
 213 Id. at 134 (quoting Chakrabarty, 447 U.S. at 311–12 (1980)). 
 214 Id. 
 215 Id. 
 216 Chakrabarty, 447 U.S. at 313. 
 217 Pioneer, 534 U.S. at 131. 
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Even though the PPA was codified in a separate chapter, Chapter 15, of 
Title 35, the Pioneer Court found this did not change the substantive rights for a 
plant patent.  The Court held “[p]lant patents under the PPA . . . have very 
limited coverage and less stringent requirements than § 101 utility patents.”218  
This meant that plant patents were easier to obtain, but less secure then a utility 
patent.  Additionally, the Court found that Chapter 15 did not state that plant 
patents were the exclusive means for protection for plants.219  Thus, plants 
could obtain utility patent protection in the alternative. 
J.E.M., however, argued the PPA and PVPA provide the exclusive means 
for protecting plants and excluded utility patent protection under § 101.220  
J.E.M. advanced that plants were not covered in § 101 prior to the passage of 
the PPA, but the Court rejected this contention and concluded the utility patent 
statute was dynamic enough to encompass new and unanticipated inventions.221  
Second, J.E.M. argued the PPA’s limitation on protection for sexually 
reproduced plants would be meaningless if Congress wanted the utility patent 
statute to encompass sexually reproduced plants.  However, the Court 
examined the legislative context surrounding the PPA’s enactment and 
concluded that Congress had very different concerns in mind: Congress felt that 
patenting sexually reproduced seeds was economically infeasible because there 
was no established market for such seeds.222  The Court found little evidence to 
indicate Congress intentionally precluded patent protection for sexually 
reproduced plants when it limited the PPA to asexually reproduced plants.223  
Finally, although the Congress codified plant patents in § 161, the Court held 
plant patents still fell within the expansive language of § 101.224 
In the alternative, J.E.M. argued that Congress intended to deny broader 
protections for utility patent protection because Congress specifically enacted 
the PVPA, which limited patent-like protection for certain sexually reproduced 
plants.225  The Court held that the PVPA does not explicitly provide that it is 
                                                                                                                   
 218 Id. at 133. 
 219 Id. 
 220 Id. 
 221 Id. at 135 (“Whatever Congress may have believed about the state of patent law and the 
science of plant breeding in 1930, plants have always had the potential to fall within the general 
subject matter of § 101, which is a dynamic provision designed to encompass new and unforeseen 
inventions.”). 
 222 Id. at 136. 
 223 Id. at 137. 
 224 Id. at 137–38. 
 225 Id. at 138. 
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the exclusive means of protecting sexually reproduced plants.226  It also held 
utility patents provide a larger scope of protection than a Plant Variety 
Protection (PVP) Certificate.227  Utility patents for plants are more difficult to 
obtain than a PVP certificate because a utility patent must be “new, useful, and 
nonobvious,”228 and breeders must describe the plant in enough detail to enable 
future breeders to make and use the invention after the patent expires.229  A 
plant breeder need only show the plant variety is “new, distinct, uniform, and 
stable”230 for a PVP certificate.231  While protections for the PVPA were 
increased,232 the PVP certificate does not grant full protections enjoyed by 
utility patents.233  The court referenced an example to explain the difference in 
protection between PVP certificates and utility patents.  PVP certificates differ 
“because a [random] breeder can use a plant that is protected by a PVP 
certificate to ‘develop’ a new inbred line while he cannot use a plant patented 
under § 101 for such a purpose.”234  Under a utility patent, there are no 
exemptions for research or saving seed.235  PVP certificates do have an 
exemption for research and saving seeds.236  Further, PVP have no patent 
claims.237  Patent claims, under 35 U.S.C. § 112(b), state “[t]he specification shall 
conclude with one or more claims particularly pointing out and distinctly 
claiming the subject matter which the inventor or a joint inventor regards as the 
invention.”238  These patent claims set forth the metes and bounds of 
protection.239  In other words, patent claims define the scope of what the patent 
                                                                                                                   
 226 Id. (“First, nowhere does the PVPA purport to provide the exclusive statutory means of 
protecting sexually reproduced plants.”). 
 227 Id. (“Because it is harder to qualify for a utility patent than for a Plant Variety Protection 
(PVP) certificate, it only makes sense that utility patens would confer a greater scope of 
protection.”). 
 228 Id. at 142 (citing 35 U.S.C. §§ 101–103). 
 229 Id. (citing 35 U.S.C. § 112). 
 230 See 7 U.S.C. § 2402(a). 
 231 Pioneer, 534 U.S. at 142. 
 232 The PVPA also protects “any variety that is essentially derived from a protected variety,” 7 
U.S.C. § 2402(c)(1), and “any variety whose production requires the repeated use of a protected 
variety,” id. § 2402(c)(3).  See Plant Variety Protection Act Amendments of 1994, § 9, 108 Stat. 
3142. 
 233 Pioneer, 534 U.S. at 143. 
 234 Id. 
 235 Id. 
 236 Plant v. Utility Patents, PERENNIAL PATENTS, http://perennialpatents.com/plantpatent-v-utili 
ty-patents/ (last visited Oct. 20, 2015).  
 237 Id. 
 238 35 U.S.C. § 112(b) (2012). 
 239 Plant v. Utility Patents, supra note 236. 
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does and does not cover.240  Plant patents have one claim.241  Utility patents are 
much broader in their protection because they can have multiple claims.242  
Additionally, utility patents can cover different types of claims, including seed 
deposit claims, trait claims, breeding methods, food product claims.243  Further, 
the Court also noted the USPTO has assigned utility plant patents for a 
significant time frame244 without inconsistent legislation from Congress, 
indicating congressional acquiescence to the PPA and PVPA.245  Thus, the 
court concluded “newly developed plant breeds fall within the terms of § 101, 
and that neither the PPA nor the PVPA limits the scope of § 101’s coverage.”246 
The Supreme Court further explored seed patents in Bowman v. Monsanto 
Co.247  Monsanto owned a patent on a genetically modified soybean known as 
the “Roundup Ready” seed, which could survive exposure to certain 
herbicides.248  Under a special licensing agreement, the seed could be sold to a 
grain elevator or the resulting crop could be consumed for personal use or sold 
in commercial markets.249  The license did not permit breeding, even though it 
was possible.250  Since the seed’s resistance to certain herbicide came from a 
genetic trait, the trait could be passed down to seeds produced by the resultant 
crop.251 
A farmer named Vernon Bowman sought to circumvent the special licensing 
agreement and avoid paying premium prices for the Roundup Ready seed.252  
Instead of purchasing the seeds, Bowman purchased an assortment of 
commodity seeds from a grain elevator.253  The batch he purchased contained 
Roundup Ready seeds intermixed with other seeds.254  Bowman planted all the 
seeds and then applied a glyphosate herbicide.255  This method killed all the 
                                                                                                                   
 240 How Do I Read A Patent? The Claims, BROWN AND MICHAELS, http://www.bpmlegal.com/ho 
wtopat5.html (last visited Oct. 20, 2015). 
 241 Plant v. Utility, supra note 236. 
 242 Id. 
 243 Id. 
 244 At the time of the opinion, the Court noted utility plant patents had been granted for “at 
least 16 years.”  Id. at 144. 
 245 Id. at 143–44. 
 246 Id. at 145. 
 247 133 S. Ct. 1761 (2013). 
 248 Id. at 1764.  The patent for this seed is U.S. Patent No. 5,352,605. 
 249 Id. 
 250 Id. 
 251 Id. at 1765. 
 252 Id. 
 253 Id. 
 254 Id. 
 255 Id. 
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non-Roundup Ready seeds and revealed the crops with the patented herbicide-
resistant genetic trait.256  Bowman harvested these crops, saved the seeds, and 
replanted the patented Roundup Ready seed without paying Monsanto.257 
Monsanto sued Bowman for patent infringement of its Roundup Ready 
seed.258  Bowman raised the patent exhaustion defense.259  The district court 
found Bowman infringed on Monsanto’s patents and the Federal Circuit 
affirmed.260   
The Supreme Court held the patent exhaustion doctrine does not permit a 
farmer to save seeds from resulting crops under Monsanto’s special licensing 
agreement.261  The Court explained that the patent exhaustion doctrine 
constrains the patent holder’s right to control another’s right to a particular 
article of the patented invention.262  Once the patentee has received a reward 
for the particular article of the patented product, he or she retains no further 
control.263  However, the patentee maintains the ability to prevent the buyer to 
reproduce the particular article of the patented technology.264  Based on this 
rationale, the Supreme Court held Bowman was not entitled to the patent 
exhaustion defense while he had a right to use the original seeds he purchased, 
he needed Monsanto’s permission to harvest reproduced seeds from their 
patented Roundup Ready seeds.265 
In examining plant patents, the Court considered the Pioneer case and the 
PVPA.266  Here, the Court reaffirmed that a patent holder of a genetically 
modified seed, but not a holder of a PVP certificate, can preclude a buyer from 
saving seeds from the resulting crop.267  The court referred back to the Pioneer 
case, which concluded the “Patent Act, unlike the PVPA, contains ‘no 
exception’ for ‘saving seed.’ ”268  Thus, buyers of a patented seed under § 101 
could not save, and subsequently, breed the seed.  The Court reasoned a patent 
would dramatically decrease in value after the first transaction if farmers could 
                                                                                                                   
 256 Id. 
 257 Id. 
 258 Id. 
 259 Id. 
 260 Id. 
 261 Id. at 1763. 
 262 Id. 
 263 Id. 
 264 Id. 
 265 Id. at 1766. 
 266 Id. at 1767. 
 267 Id. 
 268 Id. 
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save seeds from the patented plant269 and create stockpiles of herbide resistant 
seeds. 
Bowman countered that the exhaustion defense applied in this case because 
farmers normally harvest seeds from crops for subsequent growing seasons.270  
In dismissing this argument, the Court equated harvesting seeds from the 
resulting crop to making a new product.271  In the alternative, Bowman argued 
that seeds naturally self-replicate, and thus, it was the planted seed that violated 
the patent, not Bowman.272  The Court concluded Bowman’s conduct made 
him more than a passive observer; rather, he maintained reproduction of the 
seeds for eight generations.273 
In the concluding paragraph of the opinion, the Court limited its holding to 
Bowman’s seed reproduction and not to other self-replicating technologies.274  
The Court declined to address patent exhaustion scenarios where the self-
replication happens outside the purchaser’s control or self-replication is a step 
in using the particular article for another purpose.275 
It is fairly clear that a plant can be patented through either a utility patent or 
a plant patent, or can receive patent-like protections under a PVPA certificate.  
However, cannabis presents another unique issue: can someone patent a plant 
that society considers harmful or immoral?  This question invokes a concept in 
patent law known as the moral utility doctrine, which means, “not be frivolous, 
or injurious to the well-being, good policy, or good morals of society.”276  
Considering the moral utility in a patent is virtually irrelevant if a utilitarian 
purpose exists. In Juicy Whip, Inc. v. Orange Bang, Inc., the Federal Court 
considered this moral utility doctrine277 and found that a patent is not invalid 
because it could be used for an immoral purpose.278  Juicy Whip, Inc. owned a 
patent279 for a drink dispenser with a simulated pre-mix tank on top of the 
dispenser.280  The tank gives the visual impression as if the tank is the principal 
                                                                                                                   
 269 Id. at 1768. 
 270 Id. 
 271 Id. 
 272 Id. at 1768–69. 
 273 Id. at 1769. 
 274 Id. 
 275 Id. 
 276 Lowell v. Lewis, 1 Mason 82 (Cir. D. Mass. 1817), abrogated by In re Fisher, 421 F.3d 1365, 
1371 (Fed. Cir. 2005). 
 277 Juicy Whip, Inc. v. Orange Bang, Inc., 185 F.3d 1364 (Fed. Cir. 1999). 
 278 Id. at 1368. 
 279 POST-MIX BEVERAGE DISPENSER WITH AN ASSOCIATED SIMULATED VISUAL DISPLAY OF 
BEVERAGE, U.S. Patent No. 5,575,405 (filed Apr. 18, 1996) (issued Nov. 19, 1996). 
 280 185 F.3d at 1365. 
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source of the bowl’s contents; however, the true source of the beverage is 
mixed immediately before being dispensed underneath the cabinet.281  Juicy 
Whip sued Orange Bang, Inc. for a patent infringement claim.282  Subsequently, 
Orange Bang, Inc. successfully moved for summary judgment at the district 
court level, holding that Juicy Whip’s patent was invalid because it lacked utility 
and could not be patented under § 101.283  
On appeal, the Federal Circuit overturned the judgment of the district court 
because there was no basis to hold that the invention lacked utility simply 
because it could fool some members of the public.284  The Federal Circuit 
reasoned the threshold for finding an invention satisfied utility is only whether 
that invention is capable of providing some identifiable benefit.285  The Court 
held that the fact one product could be held to look like another invention is a 
specific benefit in itself.286 
Even though the invention may deceive customers, the utility requirement 
was not a mandate for the USPTO to serve as arbiters of deceptive trade 
practices.287  Rather, the Court found this decision best left to other 
administrative agencies, like the Food and Drug Administration, to protect 
consumers from fraud and deception.288 
While the Supreme Court has not specifically decided on the doctrine of 
moral utility, it has identified a categorical exclusion to patentable subject 
matter, notwithstanding a product’s utilitarian value.  In Bilski v. Kappos,289 the 
Supreme Court held the “machine-or-transformation test” is not the sole test 
for determining the patent eligibility of a process.290  In affirming the Federal 
Circuit opinion, the Court addressed three specific exceptions to patentable 
subject matter under § 101.  In referencing the Chakrabarty opinion, the Bilski 
Court found only “laws of nature, physical phenomena, and abstract ideas”291 
are not patentable under § 101.  Outside of these exceptions, the Bilski Court 
found Congress took a broad, permissive approach to patent eligibility under 
                                                                                                                   
 281 Id. 
 282 Id. at 1366. 
 283 Id. 
 284 Id. at 1368. 
 285 Id. at 1366. 
 286 Id. at 1367. 
 287 Id. at 1368. 
 288 Id. 
 289 561 U.S. 593 (2010). 
 290 Id.  The facts underlying the opinion are not relevant to this analysis. 
 291 Id. at 601. 
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§ 101.292  In the aftermath of Bilski, it appears the Supreme Court interpreted 
§ 101 broadly to include many areas for innovation as long as an invention does 
not fall into one of the aforementioned categorical exclusions.  
While the aforementioned cases do not specifically address whether a strain 
of marijuana is patentable, they may provide guidance by analogy for this form 
of novel patentable subject matter. 
G.  CURRENT PATENTS GRANTED FOR CANNABIS AND PATENT PENDING 
DEVELOPMENTS 
While the Federal Government explicitly prohibits cannabis possession, use, 
distribution, and cultivation under the CSA, ironically, the federal government 
itself owns a patent for cannabis.  U.S. Patent No. 6630507, named 
“Cannabinoids as Antioxidants and Neuroprotectants” was issued on October 
7th, 2003.  The patent abstract states: 
Cannabinoids have been found to have antioxidant properties, 
unrelated to NMDA receptor antagonism.  This newfound 
property makes cannabinoids useful in the treatment and 
prophylaxis of wide variety of oxidation associated diseases, such 
as ischemic, age-related, inflammatory and autoimmune diseases.  
The cannabinoids are found to have particular application as 
neuroprotectants, for example in limiting neurological damage 
following ischemic insults, such as stroke and trauma, or in the 
treatment of neurodegenerative diseases, such as Alzheimer’s 
disease, Parkinson’s disease and HIV dementia.  
Nonpsychoactive cannabinoids, such as cannabidoil, are 
particularly advantageous to use because they avoid toxicity that 
is encountered with psychoactive cannabinoids at high doses 
useful in the method of the present invention.293 
The patent does not give the federal government a patent on the cannabis plant 
because the plant is a product of nature.  It rather patents a method of use of a 
                                                                                                                   
 292 Id.  The Court took a broad permissive approach “to ensure that “ ‘ingenuity should receive 
a liberal encouragement.’ ” Id. (quoting Diamond v. Chakrabarty, 447 U.S. 303, 308–09 (1980)). 
 293 Cannabinoids as Antioxidants and Neuroprotectants, U.S. Patent No. 6630507 (filed Feb. 2, 
2001) (issued Oct. 7, 2003). 
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non-psychoactive cannabinoid compound for treating some diseases.294  The 
patent does not claim a composition of matter or a compound, but rather a 
method for using specific cannabinoids for treating oxidative stress.295  Other 
marijuana patents have been granted for methods of use and marijuana 
associated products, but none have been granted for particular cannabis 
strains.296 
Today, a medical marijuana product exists as a consumable product in the 
prescription drug industry.  On May 31, 1985, the Federal Drug Administration 
(FDA) approved Marinol for marketing in the United States.297  Marinol 
incorporates Dronabinol in soft gelatin capsules.298  Dronabinol is a synthetic 
delta-9-tetrahydrocannibinol, commonly known as THC.299  The purpose of 
Marinol is to treat “anorexia with weight loss in patients with AIDS”300 and 
“nausea and vomiting associated with cancer chemotherapy in patients who 
have failed to respond adequately to conventional antiemetic treatments.”301  
Side effects for the drug could include abdominal pain, nausea, vomiting, 
amnesia, anxiety, confusion, depersonalization, dizziness, euphoria, 
hallucination, paranoia, somnolence, and “thinking abnormal.”302  “[Marinol] 
ha[s] been through FDA’s rigorous approval process and [has] been determined 
to be safe and effective.”303  The FDA approval process necessitates “solid 
clinical data” along with “a scientifically based assessment of the risks and 
benefits” to assess the therapeutic value of drugs.304  
                                                                                                                   
 294 Andrew Chadeayne, Does U.S. Patent No. 6,630,507 Give the Government Ownership of 
Marijuana?, INVESTING PATENTS-OWNING IDEAS, http://inventingpatents.com/us-patent-66305 
070-methods-using-marijuana/ (last visited Nov. 15, 2015). 
 295 Id. 
 296 For more information, view the USPTO Patent Full-Text and Image Database and search 
for “cannabis.”  USPTO Patent Full-Text and Image Database, http://patft.uspto.gov/netacgi/ 
nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.ht 
ml&r=0&f=S&l=50&TERM1=cannabis&FIELD1=&co1=AND&TERM2=&FIELD2=&d=P
TXT (last visited Nov. 15, 2015). 
 297 Testimony of Robert J. Meyer, M.D., http://www.fda.gov/newsevents/testimony/ucm1147 
41.htm. 
 298 Marinol, http://www.fda.gov/ohrms/dockets/dockets/05n0479/05N-0479-emc0004-04.pdf 
(last visited Nov. 15, 2015). 
 299 Id. 
 300 Id. 
 301 Id. 
 302 Id.  In clinical trials, the incidence rates of the side effects were 3% to 10%.  Id.  
 303 Testimony of Robert J. Meyer, M.D., http://www.fda.gov/newsevents/testimony/ucm114 
741.htm (last visited Nov. 15, 2015). 
 304 Id. Any drug marketed in the United States must undergo rigorous scientific testing under 
the Pure Food and Drug Act of 1906.  Http://www.dea.gov/divisions/sea/in_focus/marinol-
cessmet.pdf (last visited Nov. 15, 2015). 
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Marinol is a Schedule III drug305 regulated under the CSA, and is considered 
“abusable.”306  The DEA helped facilitate research of THC’s therapeutic effects 
on nausea and vomiting in the early 1980s.307  The research led to classification 
of Marinol as a Schedule III drug.308  In a 1999 report by the Institute of 
Medicine, the Institute did not recommend smoked marijuana for diseases 
treatable by cannabinoids, but it found that compounds in marijuana could be 
isolated in purified and synthetic forms in pharmaceuticals.309 
While Marinol’s legality as a controlled substance indicates the federal 
government is open to legalizing THC-like substances, it has never allowed a 
patent of a cannabis strain.  Scarce to no legal precedent exists for cannabis 
varieties.  In fact, many cannabis varieties are patent-pending before the 
USPTO.310  But, the USPTO has not granted a patent to a cannabis strain yet.311  
According to the Jason Blevins, a writer for the Denver Post, “[t]he U.S. Patent 
and Trademark Office has rejected cannabis-related patents consistently, 
arguing that the invention is ‘immoral and scandalous’ because marijuana is 
illegal or that the invention has no useful purpose because its use violates 
federal drug law.”312  An eager grower can file a standard patent application 
with the USPTO, but he or she will likely run into federal inaction.313  Further, 
the USPTO website states, “the average patent application pendency is 24.6 
months.”314  Given that it will take two years from the date of filing to reach a 
                                                                                                                   
 305 According to the DEA, “Schedule III drugs, substances, or chemicals are defined as drugs 
with a moderate to low potential for physical and psychological dependence.  Schedule III drugs 
abuse potential is less than Schedule I and Schedule II drugs but more than Schedule IV.”  Drug 
Schedules, http://www.dea.gov/druginfo/ds.shtml (last visited Nov. 15, 2015). 
 306 Marinol, http://www.fda.gov/ohrms/dockets/dockets/05n0479/05N-0479-emc0004-04.pdf 
(last visited Nov. 15, 2015). 
 307 Pharmaceutical products already exist, called Marinol and Cesamet.  Http://www.dea.gov/ 
divisions/sea/in_focus/marinol-cessmet.pdf (last visited Nov. 15, 2015). 
 308 Id. 
 309 Id. 
 310 For an example of a patent-pending cannabis strain that is still in application phase, see, Patent 
Application 61923707, United States Patent and Trademark Office Patent Application Full Text and 
Image Database, http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1 
&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=24&f=G&l=50&co1=AND&=PG01&s1=c 
annabis.CLM.&OS=ACLM/cannabis&RS=ACLM/cannabis (last visited Oct. 20, 2015). 
 311 Hilary Bricken, The Possibility of Marijuana Plant Patents, http://abovethelaw.com/2015/07/th 
e-possibility-of-marijuana-plant-patents/ (last visited Oct. 20, 2015). 
 312 Jason Blevins, Pot Grower’s Quest: U.S. Patent Protection for Cannabis Seeds, http://www.thecan 
nabist.co/2014/12/24/cannabis-seeds-pot-growers-us-patent-protection/25975/2/ (last visited 
Oct. 20, 2015). 
 313 Id. 
 314 Patent FAQs, UNITED STATES PATENT AND TRADEMARK OFFICE, http://www.uspto.gov/ 
help/patent-help (last modified Dec. 13, 2014). 
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patent grant or denial, the only benefit from the patent application process a 
grower can hope for is a patent-pending designation315 on his or her strain. 
III.  ANALYSIS 
The legal muddle explained above provides little guidance for whether 
cannabis strains are patentable, and a cannabis strain has never been patented.  
While case law from the Federal Circuit provides some guidance for plant 
patents in the corn industry,316 it is unclear whether a plant patent can be issued 
for a cannabis variety.  Thus, growers are left in legal limbo. 
Initially, since the cannabis plant is a product of nature, it cannot be 
patented.317  Thus, while naturally occurring compounds are not patentable, 
synthetic compounds and purified components of marijuana are patentable as 
chemical inventions.318  Additionally, new combinations of the molecules found 
in marijuana are patentable.319  
First, this Part will establish the underlying issues for cannabis variety 
patents.  This Part will then analyze the major impediments to patentability and 
the underlying rationale for those obstacles.  This Part will also evaluate some 
clear answers that have emerged from analogous patent law.  Further, this Part 
will suggest a legal analytical framework for growers seeking to patent their 
respective cannabis strains.  This framework considers salient questions of 
patent law: what avenues a cultivator could choose for his or her cannabis 
variety patent, the current federal prohibition, and its effect on cannabis variety 
patents.  Next, this Part will answer the central question posed by this Note: 
whether a cannabis strain is patentable, and how a grower could go about 
receiving legal protection for their strain.  Given the current state of federal law, 
this Part will assert that cannabis strains are patentable, using analogous case 
law and the underlying policy of patent law in general.  Finally, this Part will 
address potential legislative developments that may change the analytical 
framework and the conclusion reached by this Note. 
                                                                                                                   
 315 “When a patent application is pending, the manufacturer is able to use the term ‘patent-
pending’ on the product or in advertisements.”  Bonnie Grant, Deficiencies and Proposed Recommendation 
to the False Marking Statute: Controlling Use of the Term ‘Patent,’ 12 J. INTELL. PROP. L. 283 (2004). 
 316 See Monsanto Co., 133 S. Ct. at 1761; see also Pioneer, 534 U.S. at 124. 
 317 Does U.S. Patent No. 6,630,507 Give the Government Ownership of Marijuana?, http:// 
inventingpatents.com/us-patent-66305070-methods-using-marijuana/ (last visited Nov. 15, 2015). 
 318 Patenting Marijuana Technology, INVENTINGPATENTS.COM, http://inventingpatents.com/patent 
ing-marijuana-technology/ (last visited Nov. 15, 2015). 
 319 Id. 
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A.  PATENTABILITY OF CANNABIS VARIETIES: A CLEARER PICTURE OF THE 
UNDERLYING ISSUES 
While the legal environment surrounding cannabis variety patents remains 
murky, there are some clearly definable issues and answers.  The prospective 
patentee must understand what undercuts the potential patent. 
The main impediment to patentability for cannabis varieties is the CSA.320  
Under the CSA, the DEA has labeled cannabis as a Schedule I drug, meaning it 
has no medically accepted benefit and is highly susceptible to abuse.  While 
many states legalized marijuana for medical and recreational use,321 cannabis is 
federally prohibited.  Pursuant to the CSA, the federal government can arrest 
state residents despite comporting with state marijuana laws, according to the 
Gonzales decision.322  As a result, growers will need to find a way around the 
CSA. 
This impediment has several practical impacts on the cannabis cultivation 
trade.  First and foremost, it makes cannabis cultivation illegal.  As a result, 
when cannabis cultivators apply to the patent process, they are essentially 
admitting to a federal crime.323  Cannabis cultivators thus risk criminal 
prosecution simply by applying for a patent.  Further, one purpose of the CSA 
is to limit the supply of cannabis in the market.324  The cultivation of cannabis 
varieties increases the supply of cannabis in general.  Therefore, the federal 
prohibition serves as a deterrent to cannabis cultivation, thereby limiting the 
supply in drug markets, and opportunities for innovation.  
While the CSA has effectively prevented marijuana cultivation from 
developing legal precedent in the patent arena, some clear answers exist in 
current patent law.  A patent for an extracted component of cannabis exists for 
the federal government.325  Therefore, it appears that cannabis is clearly 
patentable; however, this patent is materially limited.  A further analysis of the 
patent shows this patent does not exist for the cannabis plant, but rather for a 
non-psychoactive cannabinoid compound derived from the plant.326  Thus, the 
question as to whether cannabis varieties are patentable has not been answered.  
                                                                                                                   
 320 Controlled Substances Act, 21 U.S.C. § 801 (1970). 
 321 See COLO. CONST. art. XVIII, § 16 (2013); see also WASH. ADMIN. CODE §§ 314-55-005 
through 314-55-540 (2013).  Recently, Oregon, Alaska, and the District of Columbia have 
legalized recreational marijuana. 
 322 545 U.S. at 29. 
 323 Interview with Joseph Miller, January 4th, 2015, by this Note’s Author. 
 324 The Controlled Substances Act, 21 U.S.C. § 801 (1970). 
 325 Cannabinoids as Antioxidants and Neuroprotectants, U.S. Patent No. 6630507 (filed Feb. 2, 
2001) (issued Oct. 7, 2003). 
 326 Id. 
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Additionally, a synthetic cannabis supplement, Marinol, is readily available for 
states that have legalized medical marijuana.  While it appears the federal 
government has admitted cannabis compounds have medicinal uses by 
admitting Marinol as a Schedule III drug, this still leaves the cannabis variety 
patent question open.  Therefore, while there are promising answers in this legal 
miasma, a genuine uncertainty remains for the patentability of unique cannabis 
varieties.  
B.  THE ANALYTICAL FRAMEWORK FOR GROWERS 
Given the outstanding legal question as to whether cannabis varieties are 
patentable, many corollary questions surrounding cannabis varieties have 
developed.   
The first question a cultivator must ask is whether the cannabis strain is 
patentable?  Initially, a cultivator must determine whether the cannabis product 
occurs naturally, or is a unique cannabis variety either sexually or asexually 
reproduced.  In order to answer this threshold inquiry, the cultivator must 
decide to pursue one of three routes: utility patents, PPA, or the PVPA.  
Since utility patents afford the highest level of legal protection for 
intellectual property, they are the hardest to attain.327  While a cultivator can 
develop a new composition of matter theoretically attainable under § 101, 
evidenced by the utility patents granted in Pioneer, the cultivator actually needs 
to develop a new composition of matter.  This may be above the pay grade of 
the average botanist and require sophisticated laboratory technology. 
As a result, it is more prudent for a cultivator to apply for a plant patent 
under the PPA.  Plant patents are more easily attainable than utility patents 
because fewer elements need to be proven in the patent application process.  
The precedent set forth in Pioneer indicates this is entirely possible.  The only 
restriction on plant patents is that the variety must be asexually reproduced, 
thereby limiting the vast possibilities of genetic recombination through sexual 
reproduction.  Additionally, since asexual reproduction can only be rendered 
from one mother plant,328 this may create more cost for the cultivator because a 
mother plant must be grown before an asexually reproduced plant can be 
patented. 
Thirdly, cultivators can seek protection through a PVP certificate under the 
PVPA.  PVP certificates grant patent-like protections for sexually reproduced 
                                                                                                                   
 327 Utility patents require the showing of four elements: Novelty, statutory, nonobvious, and 
Usefulness.  See supra Part II. 
 328 Wooster, supra note 184, § 2. 
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plants.  All the grower must prove for a PVP certificate is that the cannabis 
variety is new, distinct, uniform, and stable.  Thus, growers can receive legal 
protection for cannabis seeds and uncultivated plants.  However, there are some 
drawbacks to this patent route.  PVP certificates are granted by the Department 
of Agriculture, not the USPTO.  The USPTO has more expertise in dealing 
with patents generally, whereas the Department of Agriculture dedicates only 
one office to Plant Variety Patents.  Further, a PVP certificate has no claims on 
the scope of protection, whereas plant patents have one claim defining the 
bounds of protection.  Thus, PVP certificates do not afford the full amount of 
protection afforded by a plant patent under the PPA.  
A cannabis cultivator needs to thoroughly ascertain the details of the 
cultivation process needed to complete a valid patent application.  Before 
submitting the patent application, the cannabis cultivator must determine if the 
federal government will deny the patent because cannabis is a Schedule I drug 
and illegal at the federal level.  However, the Juicy Whip precedent suggests that 
the fact that cannabis is illegal under the CSA has no merit in the patent 
application process.  As long as cannabis has an identifiable utilitarian benefit, it 
satisfies the usefulness requirement, and here, a cultivator can point the medical 
benefits of cannabis.  While the court in Juicy Whip did not consider a patented 
product that was inherently illegal329 like cannabis, this Federal Circuit case 
clearly establishes that the USPTO does not look to moral utility in a patent 
application.330 
Next, the cannabis cultivator will need to assess an important risk: criminal 
liability.  The pertinent question is whether the patent application serves as an 
admission to a federal crime.  Since the patent process is an incredibly detailed 
process, a cannabis cultivator will need to fully elucidate the details of the 
activities engaged in to develop a new cannabis variety in order to complete a 
valid patent application.  Details about cultivation include growing methods, 
harvesting, and many other ways of cultivating the cannabis plant.  Further, 
patent applicants will need to delve into further specificity of their innovation 
by proving the metes and bounds of their patent claims.  While patent claims 
only apply to plant and utility patents, PVP certificates still must divulge 
information about the cannabis strain to the federal government to fulfill the 
necessary elements for the certificate.  Since cultivation of marijuana is a federal 
crime under the CSA, the prospective patentee will be reporting facts that 
                                                                                                                   
 329 The product in this case was a drink machine.  Id. at 1365–68.  By contrast, cannabis is 
inherently illegal under the CSA.  
 330 Even though the Federal Circuit has established no moral utility, it is still unclear what the 
Supreme Court will determine. 
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constitute an admission of criminal wrongdoing.  Given that the acts 
undertaken to innovate are also acts that are punishable as crimes, a person 
could technically engage in them, but only at the cost of putting themselves in 
danger of being criminally prosecuted.  Here, if the grower is willing to take the 
risk and fails, he or she may enjoy patent protection for their cannabis variety 
from the confines of a federal penitentiary.  
C.  ALTHOUGH CANNABIS IS A SCHEDULE I DRUG UNDER THE CSA, POLICY 
CONSIDERATIONS UNDERLYING PLANT PATENTS AND THE FEDERAL CIRCUIT 
CASE LAW INDICATE CANNABIS VARIETIES ARE LIKELY PATENTABLE 
Although cannabis is a Schedule I drug under the CSA, cannabis strains are 
likely patentable because the USPTO does not look into the moral utility of a 
patent.  From the face of the CSA, a grower may believe a cannabis variety 
patent is unattainable, given that cannabis cultivation is illegal at the federal 
level.  However, there is no provision in the text of the CSA prohibiting patent 
protection, through utility patents, PPA, or the PVPA.  It is safe to assert that 
the CSA did not contemplate patent law at all, but rather only criminal 
sanctions for cannabis possession and production.  Assuming the cannabis 
variety cultivated is unique and not a product of nature or another categorical 
exclusion under the Bilski precedent,331 a grower will theoretically receive a 
patent through proof of the creation of the variety and satisfactory completion 
of the patent application requirements.  
As an initial matter, under Juicy Whip, the USPTO will not look to the moral 
utility of the invention.  So long as the patent is written broadly enough to 
encompass a legitimate purpose, the fact that the invention’s use is immoral 
does not affect its patentability.  However, while there are good business 
reasons for making cannabis strains patentable, patent law usually ignores 
business considerations when determining patentability.  Thus, cannabis strains 
likely do not violate the usefulness requirement. 
Additionally, under Bowman and Pioneer, a cultivator can receive a patent for 
plants or a PVP certificate.  Further, a grower can likely preclude purchasers of 
his or her plant patent from saving seeds and growing new batches.  Thus, it 
appears that if cannabis varieties are plants and can be either sexually or 
asexually reproduced, they are patentable.  Moreover, nothing in the Bilski 
precedent precludes the broad patentable subject matter of § 101, unless a 
product is a product of nature, physical phenomena, or an abstract idea.  As 
                                                                                                                   
 331 The specific categorical exemptions are products of nature, physical phenomena, and 
abstract ideas.  Bilski, 561 U.S. at 601. 
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long as the cultivator can show he engineered the variety in aid of nature, the 
cultivator will likely get around the products-of-nature exclusion. 
Furthermore, the policy considerations underlying patent law support the 
patentability of cannabis strains.  The fundamental purpose of patent law is 
encouraging innovation of utilitarian works.332  Assuming cannabis varieties 
serve a utilitarian purpose—and medical evidence suggest they do333—
providing patents for cannabis varieties promotes innovation in an industry ripe 
with opportunity.  Cannabis cultivators will likely develop the best strains in the 
hopes of achieving legal legitimacy and protection from the federal government.  
The possibilities for invention and innovation are limitless. Preclusion of 
cannabis variety patents would likely result in a chilling effect on the cannabis 
industry as a whole.  As a result, the possibility that new varieties are discovered 
will diminish dramatically, which likely will have a substantial adverse impact on 
the development of this emerging industry.  Given that states like Colorado and 
Washington use revenues from marijuana sales to fund public goods, growth in 
the cannabis industry can funnel more money in educational projects and other 
public funds.  This benefits society in addition to the billions of dollars saved 
on law enforcement and correctional facility costs.  Furthermore, assuming 
cannabis does have a medical use, innovation in cannabis varieties may catalyze 
the development of unimagined pharmaceutical drugs and spur entirely new 
industries.  But, much of these hypothetical benefits are likely not possible 
without an economic incentive, namely, the limited monopoly afforded by 
patent law. 
Currently, economic barriers created by the CSA have limited the 
investment flowing into the cannabis industry.  Many venture capitalists and 
angel investors are wary of the cannabis industry for two reasons: one, potential 
criminal liability, and two, the industry is not the type traditionally financed by 
venture capital funds.334  While venture capitalists and cannabis cultivators are 
understandably wary of the first reason, lack of quality in the industry may be 
alleviated by the provision of cannabis variety patents.  If cannabis varieties are 
patentable, the cannabis industry gains much-needed credibility, which it 
currently lacks.  By providing this credibility, legal protection would 
consequently provide a catalyst for capital investment.  Therefore, the 
development of patent law in the corn industry, the virtual nonexistence of the 
moral utility doctrine, and the strong policy rationales underlying patent law 
support the idea that cannabis varieties should be patentable. 
                                                                                                                   
 332 Sartori, supra note 153, at 336 (discussing the economic incentives theory in patent law). 
 333 See supra note 93. 
 334 Ohmer, supra note 59, at 113–14. 
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D.  LEGISLATIVE DEVELOPMENTS THAT CAN CHANGE THE LEGAL 
ENVIRONMENT 
While cannabis varieties are likely a patentable subject matter, legislative 
enactments, executive action, and administrative capitulation by the USPTO 
can provide more assurance for a cannabis cultivator that his or her variety is 
patentable.  The CSA was a product of congressional action.  Accordingly, 
Congress is in the best position to effectuate change favoring cannabis variety 
patents.  Congress could expressly allow cannabis patents through law. 
More feasibly, Congress could allow the Attorney General to give states with 
regulatory schemes immunity from federal prosecution under the CSA.  This 
could potentially resolve the conflict between state and federal laws on 
marijuana legalization.  The federal government would then have leverage in 
ensuring state compliance with federal drug enforcement objectives, while also 
resolving the fear of federal prosecution on the part of those growers operating 
legally in states. Conversely, Congress could also specifically prohibit cannabis 
variety patents by statute.  Here, the issue is not Congress’s constitutional 
authority to act, but rather those political realities of congressional legislation. 
Executive action by the President could also effectuate change in this legal 
environment.  The President could reschedule marijuana from a Schedule I to a 
Schedule II drug and this seems like more of a reality in the wake of former 
Attorney General Eric Holder’s comments in favor of this move.  This would 
drastically change the legal environment.  Such a move will likely be politically 
motivated, as it rests with the president’s discretion.  Furthermore, the federal 
government could choose not to prosecute the person making a cannabis 
variety claim.  It appears from the Department of Justice memo that this may 
occur because such prosecution does not fulfill the priorities of federal 
enforcement.335  However, this still leaves open significant risk to the 
prospective cannabis variety patent applicant because there is always uncertainty 
about prosecutorial discretion. 
Finally, if the patent-pending cannabis strain is granted by the USPTO, the 
precedent for marijuana strains is clear: it is allowed.  Currently, the USPTO has 
not granted a cannabis strain patent citing marijuana’s illegality under federal 
                                                                                                                   
 335 Justice Department Announces Update to Marijuana Enforcement Policy, United States Department 
of Justice (2013), http://www.justice.gov/opa/pr/justice-department-announces-update-marijua 
na-enforcement-policy (explaining the federal enforcement priorities emphasize prevention of 
distribution to minors, distribution to criminal enterprises, distribution to states where marijuana 
is illegal, using marijuana as a cover for other drugs, use of firearms in distribution of marijuana, 
impaired driving and other adverse consequences, growing on public lands, and possession or use 
of marijuana on public lands). 
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law.336 Therefore, cannabis strains will not be issued without USPTO 
capitulation.  Capitulation will likely not happen.  However, in the event 
cannabis strains become patentable through congressional, executive, or 
administrative action, cannabis variety patents will likely emerge as a new 
patentable subject matter ripe for innovation. 
IV.  CONCLUSION 
With its gradual legitimization, the cannabis industry is ripe for innovation.  
Embedded within this industry is the emergence of a new patentable subject 
matter: cannabis variety patents.  While virtually unregulated before the turn of 
the twentieth century, cannabis endured more than a century of stigmatization 
and regulation, ultimately leading to its illegality nationwide through the 
Controlled Substances Act.  Currently, marijuana is a Schedule I narcotic, 
meaning it has a high potential for abuse and no accepted medical uses. 
However, the times are changing.  Many studies today indicate more public 
support for marijuana decriminalization and legalization.  In the face of the 
federal prohibition, many states like Colorado and Washington have not only 
legalized marijuana for medical use, but also for recreational use.  Recently, the 
Department of Justice, the entity that prosecutes federal criminal offenses for 
possession and cultivation of marijuana, issued a memorandum indicating it 
would not employ its limited prosecutorial resources against individuals and 
businesses in states that have legalized cannabis recreationally, as long as the 
states have strict regulatory schemes in place.  Furthermore, the federal 
government itself has patented a method-of-use for cannabis and has approved 
a drug utilizing synthetic THC to treat many medical ailments. 
Yet, while a marijuana patent exists, no patents have been issued for 
cannabis variety strains.  Despite this fact, case law from the Supreme Court 
and the Federal Circuit, along with persuasive policy considerations, suggest 
that a cannabis strain is patentable.  If patentable, a grower could receive patent 
protection through one of three avenues: utility patents, plant patents, or the 
Plant Variety Protection Act certificates. 
However, despite these favorable indications, the CSA is a virtually 
impervious barrier to patentability.  Federal law reigns supreme over state 
legalization, as held in the Gonzales precedent.  Patent law is exclusively within 
federal jurisdiction, and consequently, the legal domain follows federal law.  
                                                                                                                   
 336 Jason Blevins, Pot Grower’s Quest: U.S. Patent Protection for Cannabis Seeds, http://www.thecannabi 
st.co/2014/12/24/cannabis-seeds-pot-growers-us-patent-protection/25975/2/ (last visited Oct. 20, 
2015). 
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Cultivators who apply for patent protection must be wary of the federal ban 
because details divulged during the patent application likely constitute 
admissions to a federal crime under the CSA.  There are solutions to this 
problem.  Congress could resolve the conflict between federal and state laws 
through a statute.  The president could change the Schedule I status of cannabis 
to Schedule II or less.  Or, the USPTO could capitulate and outright issue a 
patent for a cannabis strain.  However, unless some legal change occurs, 
cannabis strains are not patentable. 
Cannabis cultivators and venture capitalists are eager to see where federal 
law is going in light of state legalization and changing political realities.  Legal 
developments surrounding cannabis at the federal level are likely to occur in the 
near future.  For any real change to happen, the federal government must act.  
One thing is for certain, however: a small window of opportunity in this 
industry will propel it to new highs. 
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